194 related articles for article (PubMed ID: 24722184)
1. Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Azimi A; Pernemalm M; Frostvik Stolt M; Hansson J; Lehtiö J; Egyházi Brage S; Hertzman Johansson C
Br J Cancer; 2014 May; 110(10):2489-95. PubMed ID: 24722184
[TBL] [Abstract][Full Text] [Related]
2. Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.
Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
Melanoma Res; 2002 Aug; 12(4):335-42. PubMed ID: 12170182
[TBL] [Abstract][Full Text] [Related]
3. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Kiebert GM; Jonas DL; Middleton MR
Cancer Invest; 2003; 21(6):821-9. PubMed ID: 14735685
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide for Treating Malignant Melanoma.
Li RH; Hou XY; Yang CS; Liu WL; Tang JQ; Liu YQ; Jiang G
J Coll Physicians Surg Pak; 2015 Sep; 25(9):680-8. PubMed ID: 26374366
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.
Kim C; Lee CW; Kovacic L; Shah A; Klasa R; Savage KJ
Oncologist; 2010; 15(7):765-71. PubMed ID: 20538743
[TBL] [Abstract][Full Text] [Related]
7. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Treudler R; Georgieva J; Geilen CC; Orfanos CE
J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
[TBL] [Abstract][Full Text] [Related]
8. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
Turley RS; Tokuhisa Y; Toshimitsu H; Lidsky ME; Padussis JC; Fontanella A; Deng W; Augustine CK; Beasley GM; Davies MA; Dewhirst MW; Tyler DS
Ann Surg; 2015 Feb; 261(2):368-77. PubMed ID: 24646553
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Agarwala SS; Kirkwood JM
Oncologist; 2000; 5(2):144-51. PubMed ID: 10794805
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy.
Ma S; Egyházi S; Ringborg U; Hansson J
Oncol Rep; 2002; 9(5):1015-9. PubMed ID: 12168066
[TBL] [Abstract][Full Text] [Related]
12. The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
Guida M; Tommasi S; Strippoli S; Natalicchio MI; De Summa S; Pinto R; Cramarossa A; Albano A; Pisconti S; Aieta M; Ridolfi R; Azzariti A; Guida G; Lorusso V; Colucci G
BMC Cancer; 2018 May; 18(1):552. PubMed ID: 29747595
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H; Polyzos A; Stavrinidis I; Frangia K; Tsoutsos D; Panagiotou P; Markopoulos C; Papadopoulos O; Pectasides D; Mantzourani M; Middleton M; Vaiopoulos G; Fountzilas G
Ann Oncol; 2006 Dec; 17(12):1835-41. PubMed ID: 16980601
[TBL] [Abstract][Full Text] [Related]
14. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Fateh S; Schell TD; Gingrich R; Neves RI; Drabick JJ
Cancer Biol Ther; 2010 Dec; 10(11):1091-7. PubMed ID: 20930514
[TBL] [Abstract][Full Text] [Related]
15. Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
Thangasamy T; Sittadjody S; Mitchell GC; Mendoza EE; Radhakrishnan VM; Limesand KH; Burd R
BMC Cancer; 2010 Jun; 10():282. PubMed ID: 20540768
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
Zheng M; Bocangel D; Ramesh R; Ekmekcioglu S; Poindexter N; Grimm EA; Chada S
Mol Cancer Ther; 2008 Dec; 7(12):3842-51. PubMed ID: 19056673
[TBL] [Abstract][Full Text] [Related]
17. A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells.
Biteghe FN; Davids LM
J Photochem Photobiol B; 2017 Jan; 166():18-27. PubMed ID: 27852006
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
[TBL] [Abstract][Full Text] [Related]
19. [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis].
Frick S; Lischner S; Rosien F; Haacke TC; Schäfer F; Christophers E; Hauschild A
Hautarzt; 2002 Oct; 53(10):659-65. PubMed ID: 12297947
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]